Suven Life Sciences has received three product patents one each from Australia, Sri Lanka and South Korea corresponding to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2019.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and schizophrenia.

With these new patents, Suven has a total of 16 patents in Australia, nine patents in Sri Lanka and 12  patents in South Korea. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Product out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.

Venkat Jasti, CEO said, “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.”

Suven has 12 internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and schizophrenia.